Literature DB >> 18767174

Use of combined molecular biomarkers for prediction of clinical outcomes in locally advanced tonsillar cancers treated with chemoradiotherapy alone.

Yih-Lin Chung1, Ming-Yuan Lee, Cheng-Fang Horng, James Jer-Ming Jian, Skye Hongiun Cheng, Stella Y Tsai, Cheng-I Hsieh, Lawrence K Yen, Ching-Yuan Lin.   

Abstract

BACKGROUND: Environmental exposures to tobacco, alcohol, human papillomavirus (HPV) and/or Epstein-Barr virus (EBV), all of which can perturb multiple cell cycle proteins or tumor suppressors, have been implicated in the pathogenesis of different subsets of head and neck cancers. The aim of this study was to investigate to which extent the virus infection by itself, and/or the altered cell cycle proteins, contributes to prognosis in locally advanced tonsillar squamous cell carcinomas (TSCCs) treated with concurrent chemoradiotherapy (CCRT) alone.
METHODS: Serial tumor tissue arrays from archival samples were tested for the presence of HPV genome integration or EBV episome by means of DNA sequencing, real-time polymerase chain reaction (PCR), and in situ hybridization. Alterations of cell cycle proteins (p53, pRb, and p21) were evaluated by immunohistochemical staining. The association of viral presence with altered cell cycle proteins was correlated to clinical outcomes.
RESULTS: Of the 46 patients with the same T2N2bM0 stage IVA among consecutive patients with TSCC, 23 (50%) had integrated HPV DNA and only 1 (2%) had EBV episome. The HPV types detected were almost all HPV-16. A reduced expression pattern of p53, pRb, and p21 was noted in HPV-positive tumors, and the incremental number of alterations in the 3 proteins was significantly associated with HPV-negative tumors. The presence or absence of HPV together with the number of altered expression of the 3 cell cycle markers resulted in further identification of 4 biologically and clinically distinct subgroups with different outcomes after CCRT.
CONCLUSIONS: Use of combined biomarkers of oncogenic HPV and tumor suppressors of p53, pRb, and p21 in advanced TSCC provides prognostic molecular classification superior to the TNM stage system and identifies low-risk patients for organ preservation by CCRT alone and high-risk patients who might benefit from planned tonsillectomy and neck dissection before or after CCRT. (c) 2008 Wiley Periodicals, Inc. Head Neck, 2009.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18767174     DOI: 10.1002/hed.20913

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  5 in total

1.  Prognostic biomarkers for HNSCC using quantitative real-time PCR and microarray analysis: β-tubulin isotypes and the p53 interactome.

Authors:  Sharon Lobert; Mary E Graichen; Robert D Hamilton; Karen T Pitman; Michael R Garrett; Chindo Hicks; Tejaswi Koganti
Journal:  Cytoskeleton (Hoboken)       Date:  2014-11-22

2.  Detection and significance of human papillomavirus, CDKN2A(p16) and CDKN1A(p21) expression in squamous cell carcinoma of the larynx.

Authors:  Rebecca D Chernock; Xiaowei Wang; Ge Gao; James S Lewis; Qin Zhang; Wade L Thorstad; Samir K El-Mofty
Journal:  Mod Pathol       Date:  2012-09-21       Impact factor: 7.842

3.  Rising incidence of HPV positive oropharyngeal cancer in Taiwan between 1999 and 2014 where betel nut chewing is common.

Authors:  Cheng-Ping Wang; Tseng-Cheng Chen; Wan-Lun Hsu; Jenn-Ren Hsiao; Peir-Rong Chen; Mu-Kuan Chen; Chun-Hung Hua; Ming-Hsui Tsai; Jenq-Yuh Ko; Pei-Jen Lou; Chun-Ju Chiang; Chen-Tu Wu; Yih-Leong Chang
Journal:  BMC Cancer       Date:  2022-03-21       Impact factor: 4.430

4.  Prognostic value of some tumor markers in unresectable stage IV oropharyngeal carcinoma patients treated with concomitant radiochemotherapy.

Authors:  Erika Soba; Marjan Budihna; Lojze Smid; Nina Gale; Hotimir Lesnicar; Branko Zakotnik; Primoz Strojan
Journal:  Radiol Oncol       Date:  2015-11-27       Impact factor: 2.991

5.  Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients.

Authors:  Géraldine Descamps; Yasemin Karaca; Jérôme R Lechien; Nadège Kindt; Christine Decaestecker; Myriam Remmelink; Denis Larsimont; Guy Andry; Samantha Hassid; Alexandra Rodriguez; Mohammad Khalife; Fabrice Journe; Sven Saussez
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-01       Impact factor: 4.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.